RBC transfusions among hemodialysis patients (1999-2010): Influence of hemoglobin concentrations below 10 g/dL

American Journal of Kidney Diseases

Volumn 62, Issue 5, 2013, Pages 919-928

  Gilbertson, David T ^a   Monda, Keri L ^b   Bradbury, Brian D ^b   Collins, Allan J ^a  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b AMGEN INC   (United States)

Author keywords

Hemodialysis; hemoglobin concentration; red blood cell transfusion

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; ERYTHROCYTE TRANSFUSION; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY;

EID: 84886722509     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.05.004     Document Type: Article

References (43)

1. J.W. Eschbach, J.W. Adamson Anemia of end-stage renal disease (ESRD) Kidney Int 28 1 1985 1 5
2. Amgen Inc. Epogen (epoetin alfa) [prescribing Information]; supplement no. 5281 Approved May 2012 http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2012/103234s5281lbl.pdf 2012 Accessed April 9, 2013
3. A.J. Collins, R.N. Foley, C. Herzog US Renal Data System 2010 annual data report Am J Kidney Dis 57 1 2011 e1 e526 (suppl 1)
4. H.N. Ibrahim, A. Ishani, R.N. Foley, H. Guo, J. Liu, A.J. Collins Temporal trends in red blood transfusion among US dialysis patients, 1992-2005 Am J Kidney Dis 52 6 2008 1115 1121
5. A. Besarab, W.K. Bolton, J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 9 1998 584 590
6. A.K. Singh, L. Szczech, K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 20 2006 2085 2098
7. T.B. Drueke, F. Locatelli, N. Clyne Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 20 2006 2071 2084
8. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
9. A.J. Collins, R.N. Foley, B. Chavers United States Renal Data System 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States Am J Kidney Dis 59 1 2012 e1 e420 (suppl 1)
10. E. Lacson Jr, N. Ofsthun, J.M. Lazarus Effect of variability in anemia management on hemoglobin outcomes in ESRD Am J Kidney Dis 41 1 2003 111 124
11. J.P. Ebben, D.T. Gilbertson, R.N. Foley, A.J. Collins Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations Clin J Am Soc Nephrol 1 6 2006 1205 1210
12. S. Fishbane, J.S. Berns Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin Kidney Int 68 3 2005 1337 1343
13. P.L. Hebert, L.S. Geiss, E.F. Tierney, M.M. Engelgau, B.P. Yawn, A.M. McBean Identifying persons with diabetes using Medicare claims data Am J Med Qual 14 6 1999 270 277
14. Amgen Inc. Aranesp (darbepoetin alfa) [prescribing Information], suppl no. 5285 Approved May 2012 http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2012/103951s5285lbl.pdf 2012 Accessed April 9, 2013
15. Gill KS, Muntner P, Lafayette RA, et al. Red blood cell transfusion use in patients with chronic kidney disease [published online ahead of print February 6, 2013]. Nephrol Dial Transplant. doi:10.1093/ndt/gfs580.
16. D.N. Churchill, D.W. Taylor, R.J. Cook Canadian Hemodialysis Morbidity Study Am J Kidney Dis 19 3 1992 214 234
17. US Renal Data System USRDS 1999 Annual Data Report 1999 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
18. D.T. Gilbertson, Y. Peng, B. Bradbury, J.P. Ebben, A.J. Collins Hemoglobin level variability: anemia management among variability groups Am J Nephrol 30 6 2009 491 498
19. B.D. Bradbury, O. Wang, C.W. Critchlow Exploring relative mortality and epoetin alfa dose among hemodialysis patients Am J Kidney Dis 51 1 2008 62 70
20. A. Ishani, C.A. Solid, E.D. Weinhandl, D.T. Gilbertson, R.N. Foley, A.J. Collins Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death Nephrol Dial Transplant 23 5 2008 1682 1689
21. B.D. Bradbury, M.A. Brookhart, W.C. Winkelmayer Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations Am J Kidney Dis 54 3 2009 554 560
22. E.D. Weinhandl, Y. Peng, D.T. Gilbertson, B.D. Bradbury, A.J. Collins Hemoglobin variability and mortality: confounding by disease severity Am J Kidney Dis 57 2 2011 255 265
23. C.A. Solid, R.N. Foley, D.T. Gilbertson, A.J. Collins Perihospitalization hemoglobin-epoetin associations in U.S. hemodialysis patients, 1998 to 2003 Hemodial Int 11 4 2007 442 447
24. D.S. Silverberg, D. Wexler, A. Iaina, S. Steinbruch, Y. Wollman, D. Schwartz Anemia, chronic renal disease and congestive heart failure - the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists Int Urol Nephrol 38 2 2006 295 310
25. G. Efstratiadis, D. Konstantinou, I. Chytas, G. Vergoulas Cardio-renal anemia syndrome Hippokratia 12 1 2008 11 16
26. B.D. Bradbury, M.D. Danese, M. Gleeson, C.W. Critchlow Effect of epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL Clin J Am Soc Nephrol 4 3 2009 630 637
27. A. Ishani, H. Guo, D.T. Gilbertson Time to target haemoglobin concentration (11 g/dl) - risk of hospitalization and mortality among incident dialysis patients Nephrol Dial Transplant 22 8 2007 2247 2255
28. D.T. Gilbertson, J.P. Ebben, R.N. Foley, E.D. Weinhandl, B.D. Bradbury, A.J. Collins Hemoglobin level variability: associations with mortality Clin J Am Soc Nephrol 3 1 2008 133 138
29. D.M. Spiegel, I. Khan, M. Krishnan, T.J. Mayne Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008 Am J Kidney Dis 55 1 2010 113 120
30. A.J. Collins ESRD payment policy changes: the new "bundled" dialysis prospective payment system (PPS) in the United States 2012 http://www.usrds.org/2012/pres/USDialysisBundle-impact-NKFCM2012.pdf Accessed April 9, 2013
31. J.W. Eschbach, J.C. Egrie, M.R. Downing, J.K. Browne, J.W. Adamson Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial N Engl J Med 316 2 1987 73 78
32. R.M. Hakim, J.C. Stivelman, G. Schulman Iron overload and mobilization in long-term hemodialysis patients Am J Kidney Dis 10 4 1987 293 299
33. R.Y. Dodd, E.P. Notari, S.L. Stramer Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population Transfusion 42 8 2002 975 979
34. G.J. Pomper, Y. Wu, E.L. Snyder Risks of transfusion-transmitted infections: 2003 Curr Opin Hematol 10 6 2003 412 418
35. K.M. Twomley, S.V. Rao, R.C. Becker Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions J Thromb Thrombolysis 21 2 2006 167 174
36. A. Shander, K. Sazama Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy Transfusion 50 5 2010 1144 1155
37. A. Vraets, Y. Lin, J.L. Callum Transfusion-associated hyperkalemia Transfus Med Rev 25 3 2011 184 196
38. F. Cardarelli, M. Pascual, N. Tolkoff-Rubin Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation Transpl Int 18 5 2005 532 540
39. S. Hardy, S.H. Lee, P.I. Terasaki Sensitization 2001 Clin Transpl 2001 271 278
40. G. Opelz Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies Lancet 365 9470 2005 1570 1576
41. H.N. Ibrahim, M.A. Skeans, Q. Li, A. Ishani, J.J. Snyder Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes Clin Transplant 25 4 2011 653 659
42. G. Opelz, B. Dohler Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades Transplantation 84 2 2007 137 143
43. C. Lefaucheur, A. Loupy, G.S. Hill Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation J Am Soc Nephrol 21 8 2010 1398 1406